Publications by authors named "Laura Chow"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

20

Total Likes

29

Extended Reach

8,287

Social Features

7
S
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.
Tricia R Cottrell, Michael T Lotze, Alaa Ali, Carlo B Bifulco, Christian M Capitini, Laura Q M Chow

J Immunother Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials.
Michael T Lotze, Tricia Cottrell, Carlo Bifulco, Laura Chow, Leslie Cope

J Immunother Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACR Appropriateness Criteria® Staging and Post-Therapy Assessment of Head and Neck Cancer.

J Am Coll Radiol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Tae Won Kim, Howard A Burris, Maria J de Miguel Luken, Michael J Pishvaian, Yung-Jue Bang, Laura Q Chow

Clin Cancer Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Laura Q M Chow, Fabrice Barlesi, Erin M Bertino, Martin J van den Bent, Heather A Wakelee

Clin Cancer Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
Laura C Kennedy, Jun Lu, Sydney Kuehn, Arturo B Ramirez, Edward Lo, Laura Q M Chow

Target Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with time to EGFR TKI treatment in patients with non-squamous metastatic non-small-cell lung cancer.
Elizabeth Marrett, Winghan Jacqueline Kwong, Laura Qm Chow

Future Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dry powders for inhalation containing monoclonal antibodies made by thin-film freeze-drying.
Stephanie Hufnagel, Haiyue Xu, Sawittree Sahakijpijarn, Chaeho Moon, Laura Q M Chow

Int J Pharm· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy.
Christina Baik, Sylvia Lee, Kitty Cook, Sarah Wallace, Rebecca Wood, Laura Chow

Cancer Treat Res Commun· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
Robert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, Shilpa Gupta, Jared Weiss

J Immunother Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Nehal J Lakhani, Laura Q M Chow, Justin F Gainor, Patricia LoRusso, Keun-Wook Lee

Lancet Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Khanh T Do, Laura Quan Man Chow, Karen Reckamp, Rachel E Sanborn, Howard Burris

Oncologist· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer.
Edward B Garon, Alexander I Spira, Melissa Johnson, Lyudmila Bazhenova, Joseph Leach, Laura Q M Chow

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Hossein Borghaei, Scott Gettinger, Everett E Vokes, Laura Q M Chow, Marco Angelo Burgio

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
Benjamin C Creelan, Tammie C Yeh, Sang-We Kim, Naoyuki Nogami, Dong-Wan Kim, Laura Q M Chow

Br J Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer.
Matthew D Hellmann, Scott Gettinger, Laura Q M Chow, Michael Gordon, Mark M Awad

Int J Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Head and Neck Cancer. Reply.
Laura Q M Chow

N Engl J Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unmet needs and opportunities for improving care for patients with advanced lung cancer on targeted therapies: a qualitative study.
Morhaf Al Achkar, Lucille Marchand, Matthew Thompson, Laura Q M Chow, Debra Revere

BMJ Open· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Cristina P Rodriguez, Qian Vicky Wu, Jenna Voutsinas, Jonathan R Fromm, Xiuyun Jiang, Laura Q M Chow

Clin Cancer Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Head and Neck Cancer.
Laura Q M Chow

N Engl J Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti-PD-1 Therapy.
Victoria Hwang, Eduardo Mendez, Laura Q M Chow, Neal David Futran, Peter Andersen

Laryngoscope· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Scott J Antonia, Hossein Borghaei, Suresh S Ramalingam, Leora Horn, Javier De Castro Carpeño, Laura Q M Chow

Lancet Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.
Scott Gettinger, Matthew D Hellmann, Laura Q M Chow, Hossein Borghaei, Scott Antonia

J Thorac Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.
Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, Jared Weiss, Iris Gluck, Laura Q M Chow

Br J Cancer· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis